Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
EVE Health Group Limited ( (AU:EVE) ) has shared an announcement.
EVE Health Group Limited has announced the launch of two innovative products: Dyspro, a fast-acting non-hormonal gummy for menstrual pain, and Libbo, a rapid-onset oral strip for erectile dysfunction. These products target the large, underserved global markets for dysmenorrhoea and erectile dysfunction, valued at US$10.92 billion and US$5.31 billion respectively. The company’s patent-pending nano-emulsion technology enhances the speed and effectiveness of these formulations. Dyspro has already been launched in Australia, with Libbo expected to follow in December, marking a significant step in the company’s commercialisation efforts.
More about EVE Health Group Limited
EVE Health Group Limited is an emerging pharmaceutical company specializing in innovative drug delivery technology. The company focuses on the women’s health market, with a pipeline that includes solutions for men’s health as well.
Average Trading Volume: 653,718
Technical Sentiment Signal: Sell
Current Market Cap: A$7.35M
For an in-depth examination of EVE stock, go to TipRanks’ Overview page.